Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0

• Published in: Rheumatology international 2014-07, Vol.34 (7), p.953-961
• Main Authors: Cobo-Ibáñez, Tatiana, Descalzo, Miguel Ángel, Loza-Santamaría, Estibaliz, Carmona, Loreto, Muñoz-Fernández, Santiago
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antibodies, Monoclonal, Murine-Derived - administration & dosage; Antibodies, Monoclonal, Murine-Derived - adverse effects; Antirheumatic Agents - administration & dosage; Antirheumatic Agents - adverse effects; Arthritis, Rheumatoid - complications; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - epidemiology; Bacterial Infections - complications; Bacterial Infections - epidemiology; Comorbidity; Connective Tissue Diseases - complications; Connective Tissue Diseases - drug therapy; Connective Tissue Diseases - epidemiology; Female; Humans; Incidence; Male; Medicine; Medicine & Public Health; Middle Aged; Opportunistic Infections - complications; Opportunistic Infections - epidemiology; Original Article; Registries - statistics & numerical data; Rheumatology; Risk Factors; Rituximab; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Virus Diseases - complications; Virus Diseases - epidemiology
• ISSN: 0172-8172; 1437-160X
• DOI: 10.1007/s00296-014-2945-y

Data on infections in patients exposed to biologic therapies are mainly focused on rheumatoid arthritis (RA). Little is known about the safety profile in other immune-mediated connective tissue diseases (ICTD). The purpose of this study was to describe and to compare the risk of serious infections (SI) in patients with RA and other ICTD on anti-TNF or rituximab and to identify predictors of SI. We analyzed RA or other ICTD patients on anti-TNF or rituximab included in the Spanish registry BIOBADASER 2.0 (2000–2011). For each disease group, incidence rate (IR), mortality rate (MR) and IR ratio (IRR) of SI with 95 % CI were estimated. Risks were then standardized by age and sex to the general population. Risk factors for SI were assessed by Poisson regression models. A total of 3,301 patients on anti-TNF ( n  = 3,166) or rituximab ( n  = 135), of which 176 (5 %) had ICTD other than RA, were analyzed. IR of SI was higher in non-RA ICTD than in RA, with an IRR of 3.15 (95 % CI 1.86, 5.31) before adjustment and 1.96 (95 % CI 1.06, 3.65) after adjustment for age, comorbidity and corticoid use. Mortality due to infections was higher in ICTD although it did not reach statistical significance. Age, disease duration, comorbidities, corticosteroids and ICTD different to RA were all independently associated with SI. Patients with ICTD other than RA are at a high risk of SI when prescribed anti-TNF or rituximab, partly due to the excess comorbidity and immunosuppressive co-treatment, but also to the inflammatory disease. When evaluating the risk/benefit ratio of off-label medications in ICTD patients, age, comorbidities and corticoid use should carefully be taken into account, applying adequate preventive measures.